向日葵(300111.SZ):子公司藥品生產許可證變更
格隆匯5月6日丨向日葵(300111.SZ)公佈,公司(以下簡稱“公司”)子公司浙江貝得藥業有限公司於近日取得浙江省藥品監督管理局換髮的《藥品生產許可證》,同意《藥品生產許可證》的變更申請。新證變更了生產範圍(受託信息),其他內容不變。
本次《藥品生產許可證》變更的內容主要是委託方浙江高跖醫藥科技股份有限公司的受託產品苯璜貝他斯汀口崩片,受託信息中增加了藥品GMP符合性檢查編號、藥品GMP符合性檢查範圍,藥品批準文號及批準文號有效期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.